The Rise of Lipid Nanoparticles

This article was originally published in The Medicine Maker.

LNP Formulations Exelead

Exelead set to double commercial manufacturing capacity by the end of 2020

With the rapid growth of personalized medicine and other technologies in the last five years, demand for liposomal drug products has reached an all time high. Due to the influx of business, we are excited to announce that we are beginning a large-scale expansion project that will allow us to meet industry demand and better serve our existing partners. 


DSC00741 (1)

Exelead Interns Host 5k Fundraiser for Little Red Door Cancer Agency

As part of their capstone project, this summer's crop of Exelead interns banded together to put on a 5k fundraiser for a locally-grown nonprofit. Little Red Door Cancer Agency works to reduce the physical, emotional and financial burdens of cancer for residents of central Indiana by providing free client services, cancer screenings and education.


Exelead Check Presentation

Liposomes and Lipid Nanoparticles as Delivery Vehicles for Personalized Medicine

At Exelead, we approach contract manufacturing with focused expertise on liposomal and PEGylated formulations to treat rare diseases and small or underserved populations. We specialize in the development and manufacture of lipid-based, parenteral drug products, and our team has more than 20 years' experience working with a wide range of preclinical, clinical and commercial customers.